Physician
Solans, Enric
Solans, Enric was paid $7.86M by Medicaid between Jan 2018 and Jul 2024, across 171 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 19% of everything it billed.
33Billing provider infoSOLANS, ENRIC
HARVEY, IL 60426
HARVEY, IL 60426
33aNPI1336148899assigned 07/18/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$7.86M
24GClaims1,100,461
24DCodes billed171
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#5 of 398
Median peer was paid$66K
This provider vs. median120×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 132,088 | $797K | |
| 2019 | 188,394 | $1.17M | |
| 2020 | 234,067 | $1.51M | |
| 2021 | 164,887 | $1.24M | |
| 2022 | 128,767 | $1.17M | |
| 2023 | 150,343 | $1.29M | |
| 2024incomplete | 101,915 | $678K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 19% | 39,851 | 32,892 | $1.48M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 7.7% | 17,387 | 16,371 | $602K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.8% | 23,712 | 17,826 | $533K |
| 80053 | Comprehensive metabolic panel | 5.6% | 88,262 | 63,102 | $443K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 5.0% | 7,683 | 6,786 | $393K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.7% | 16,674 | 15,383 | $368K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.7% | 16,655 | 15,368 | $368K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.9% | 14,062 | 12,858 | $311K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 104,399 | 65,419 | $296K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.9% | 1,471 | 1,225 | $232K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.4% | 46,387 | 19,630 | $185K |
| 81025 | 1.7% | 73,465 | 62,229 | $137K |
159 more codes
| 83735 | 1.7% | 40,918 | $135K | |
| 84484 | 1.7% | 28,035 | $131K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.5% | 8,251 | $117K |
| 88307 | 1.2% | 1,802 | $97K | |
| 83880 | 1.2% | 9,846 | $95K | |
| 82805 | 1.2% | 6,278 | $93K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 17,677 | $90K |
| 87040 | 1.1% | 8,732 | $90K | |
| 85730 | 1.1% | 30,187 | $90K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 11,122 | $88K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 10,937 | $81K |
| 85027 | <1% | 27,763 | $78K | |
| 81003 | <1% | 67,453 | $70K | |
| 87430 | <1% | 9,607 | $70K | |
| 85610 | <1% | 35,063 | $66K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,338 | $60K |
| 83690 | <1% | 18,117 | $60K | |
| 82607 | <1% | 6,811 | $40K | |
| 87186 | <1% | 6,686 | $37K | |
| 80061 | Lipid panel | <1% | 10,875 | $33K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,255 | $33K |
| 83605 | <1% | 6,628 | $32K | |
| 87486 | <1% | 1,470 | $32K | |
| 85379 | <1% | 8,413 | $31K | |
| 87581 | <1% | 1,473 | $31K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,855 | $29K |
| 82962 | <1% | 28,110 | $27K | |
| 84702 | <1% | 6,083 | $26K | |
| 82746 | <1% | 4,617 | $26K | |
| 84703 | <1% | 7,181 | $25K | |
| 86901 | <1% | 9,778 | $22K | |
| 84100 | <1% | 13,862 | $22K | |
| 86850 | <1% | 7,367 | $21K | |
| 87641 | <1% | 913 | $20K | |
| 87210 | <1% | 7,218 | $20K | |
| 87420 | <1% | 2,417 | $18K | |
| 86592 | <1% | 9,325 | $18K | |
| 87081 | <1% | 6,334 | $18K | |
| 81001 | <1% | 14,444 | $17K | |
| 87205 | <1% | 9,170 | $17K | |
| 84436 | <1% | 5,185 | $17K | |
| 86900 | <1% | 9,771 | $16K | |
| 80202 | <1% | 2,328 | $16K | |
| 80074 | <1% | 890 | $16K | |
| 82150 | <1% | 4,893 | $15K | |
| 87088 | <1% | 2,718 | $15K | |
| 88304 | <1% | 869 | $14K | |
| 84439 | <1% | 3,349 | $14K | |
| 85007 | <1% | 8,278 | $14K | |
| 87493 | <1% | 542 | $14K | |
| 82375 | <1% | 4,739 | $12K | |
| 82728 | <1% | 2,936 | $11K | |
| 87070 | <1% | 3,861 | $11K | |
| 83550 | <1% | 2,471 | $10K | |
| 83050 | <1% | 5,468 | $10K | |
| 86803 | <1% | 1,190 | $10K | |
| 82330 | <1% | 1,325 | $9K | |
| 83540 | <1% | 2,685 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 323 | $8K |
| 82570 | <1% | 3,336 | $7K | |
| 82550 | <1% | 2,915 | $6K | |
| 80081 | <1% | 209 | $6K | |
| 80164 | <1% | 1,334 | $6K | |
| 82077 | <1% | 564 | $6K | |
| 87147 | <1% | 3,046 | $6K | |
| 87077 | <1% | 2,713 | $6K | |
| 84145 | <1% | 1,122 | $5K | |
| 85018 | <1% | 6,497 | $5K | |
| 87340 | <1% | 767 | $5K | |
| 82951 | <1% | 693 | $4K | |
| 82140 | <1% | 1,080 | $4K | |
| 86140 | <1% | 1,881 | $4K | |
| 87103 | <1% | 666 | $4K | |
| 83615 | <1% | 1,770 | $4K | |
| 85046 | <1% | 1,407 | $4K | |
| 84550 | <1% | 2,219 | $4K | |
| 82009 | <1% | 2,915 | $3K | |
| 86038 | <1% | 390 | $3K | |
| 85014 | <1% | 2,871 | $3K | |
| 86762 | <1% | 657 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 193 | $3K |
| 84480 | <1% | 644 | $3K | |
| 86920 | <1% | 597 | $3K | |
| 85652 | <1% | 1,928 | $2K | |
| 87184 | <1% | 603 | $2K | |
| 87449 | <1% | 285 | $2K | |
| 82043 | <1% | 1,204 | $2K | |
| 86705 | <1% | 310 | $2K | |
| 84300 | <1% | 967 | $2K | |
| 80076 | <1% | 567 | $2K | |
| 84156 | <1% | 1,958 | $2K | |
| 82248 | <1% | 1,233 | $2K | |
| 82247 | <1% | 910 | $2K | |
| 83090 | <1% | 323 | $2K | |
| 84133 | <1% | 794 | $2K | |
| 86696 | <1% | 170 | $2K | |
| 87536 | <1% | 38 | $2K | |
| 86695 | <1% | 205 | $1K | |
| 82436 | <1% | 652 | $1K | |
| 82565 | <1% | 809 | $1K | |
| 83655 | <1% | 222 | $1K | |
| 84030 | <1% | 516 | $1K | |
| 87341 | <1% | 231 | $1K | |
| 86480 | <1% | 48 | $1K | |
| 84132 | <1% | 1,316 | $1K | |
| 87324 | <1% | 154 | $1K | |
| 82010 | <1% | 497 | $1K | |
| 87481 | <1% | 12 | $1K | |
| 84153 | <1% | 135 | $826.18 | |
| 80050 | General health panel | <1% | 1,780 | $816.54 |
| 84155 | <1% | 751 | $797.82 | |
| 80185 | <1% | 119 | $778.80 | |
| 80143 | <1% | 67 | $760.24 | |
| 84481 | <1% | 144 | $695.25 | |
| 82378 | <1% | 105 | $684.65 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14 | $662.50 |
| 83970 | <1% | 44 | $654.76 | |
| 85008 | <1% | 2,967 | $640.55 | |
| 80179 | <1% | 57 | $637.26 | |
| 86880 | <1% | 214 | $632.20 | |
| 86308 | <1% | 261 | $616.56 | |
| 87102 | <1% | 169 | $551.48 | |
| 82784 | <1% | 37 | $508.48 | |
| 87507 | <1% | 14 | $508.20 | |
| 87529 | <1% | 15 | $480.90 | |
| 84165 | <1% | 158 | $479.79 | |
| 85384 | <1% | 142 | $396.79 | |
| 86706 | <1% | 57 | $361.24 | |
| 85660 | <1% | 164 | $360.43 | |
| 84146 | <1% | 52 | $321.90 | |
| 87150 | <1% | 28 | $316.80 | |
| 84295 | <1% | 532 | $312.31 | |
| 87181 | <1% | 85 | $306.90 | |
| 89051 | <1% | 79 | $300.36 | |
| 82950 | <1% | 127 | $293.10 | |
| 87511 | <1% | 12 | $274.80 | |
| 87899 | <1% | 58 | $268.90 | |
| 88342 | <1% | 36 | $261.93 | |
| 86780 | <1% | 33 | $241.22 | |
| 88302 | <1% | 12 | $164.56 | |
| 82435 | <1% | 160 | $137.67 | |
| 82310 | <1% | 84 | $120.42 | |
| 83021 | <1% | 16 | $97.44 | |
| 84460 | <1% | 63 | $89.88 | |
| 82374 | <1% | 44 | $84.00 | |
| 82105 | <1% | 13 | $81.66 | |
| 82947 | <1% | 163 | $76.43 | |
| 84075 | <1% | 56 | $75.30 | |
| 84450 | <1% | 56 | $73.31 | |
| 84520 | <1% | 67 | $73.07 | |
| 86376 | <1% | 12 | $51.91 | |
| 84478 | <1% | 31 | $51.76 | |
| 85004 | <1% | 16 | $31.04 | |
| 82945 | <1% | 17 | $26.18 | |
| 82040 | <1% | 18 | $24.75 | |
| 84157 | <1% | 17 | $19.55 | |
| 86923 | 0% | 225 | $0.00 | |
| 80320 | 0% | 2,231 | $0.00 | |
| 86317 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.